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Abstract
Background In recent years, several biosimilar drugs, including those of infliximab, have obtained marketing authorization from 
the European Medicines Agency (EMA). Given the peculiarity of the safety profile of biological medical products (originator and 
biosimilars), the evaluation of their tolerability represents an important component of pre-marketing and post-marketing clinical 
development. For example, infliximab products may cause adverse drug reactions (ADRs) including acute infusion reactions, 
delayed hypersensitivity reactions, and loss of efficacy, as a direct consequence of immunogenicity. Therefore, specific contrain-
dications, special warnings and precautions have been introduced in the infliximab Summary of Product Characteristics (SPC).
Objective The aim was to assess the magnitude of preventable ADRs in individual case safety reports (ICSRs) having inflixi-
mab as a suspected drug across Italy (using the spontaneous reporting systems), and the probability of reporting infections, 
infusion reactions, lack of efficacy, and hypersensitivity for originator and biosimilars of infliximab.
Methods We analyzed ADRs reported across the 2015–2017 period in the databases of five Italian regions: Campania, 
Lombardy, Sicily, Tuscany, and Veneto. Preventability of ADRs was assessed using the P-method. To compare the prob-
ability of reporting infections, infusion reactions, lack of efficacy, and hypersensitivity as ADRs as opposed to other types of 
ADRs between originator and biosimilars of infliximab, we used the reporting odds ratio (ROR). For descriptive purposes, 
the number of ICSRs involving infliximab, the number of infliximab vials distributed in the aforementioned Italian regions 
and the relative reporting rate stratified by semester were reported.
Results From October 2015 to October 2017, 459 ICSRs reported infliximab as a suspected drug (222 ICSRs related to 
infliximab originator and 237 to infliximab biosimilars). In the same period, 81,906 vials of infliximab were distributed, 
resulting in a reporting rate of six ICSRs/1000 vials. Overall, 34 cases (7.41%) were categorized as preventable. The most 
frequently detected critical criteria were “documented hypersensitivity to administered drug or drug class,” “inappropri-
ate prescription for patient’s underlying medical condition” and “incorrect dose.” Biosimilars had, in adjusted analyses, 
an increased probability of being reported as suspected in ICSRs reporting infusion reactions (ROR 4.09; 95% confidence 
interval [CI] 1.26–13.32) when compared to  Remicade®. On the contrary, they had a decreased probability of being reported 
as suspected in ICSRs reporting infections or lack of efficacy (ROR 0.33; 95% CI 0.12–0.89; ROR 0.35; 95% CI 0.20–0.61).
Conclusion Our study demonstrates that, along with a rapid increase in the utilization of infliximab biosimilars across Italy, 
there was also an increase in reporting ADRs induced by infliximab biosimilars. Of the reported ADRs, 7.4% were considered 
preventable. In adjusted analyses, infliximab biosimilars were shown to have an increased probability of being reported as 
suspected drugs in infusion reactions and a decreased probability of being reported as suspected drugs in cases of lack of 
efficacy or infection. Considering the potential advantages offered by the utilization of biosimilars in clinical practice, we 
believe that the use of biosimilars, including those of infliximab, should be supported. In order to achieve this aim, increased 
knowledge on safety and efficacy of biosimilar drugs should be obtained from real world clinical practice.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4025 9-018-0313-2) contains 
supplementary material, which is available to authorized users.
Extended author information available on the last page of the article
608 C. Scavone et al.
Key Points 
Our study demonstrated that the rapid increase in the 
utilization of infliximab biosimilars across Italy dur-
ing 2015–2017 has been accompanied by an increase 
in reporting infliximab biosimilar-induced adverse drug 
reactions. Overall, 459 individual case safety reports 
reported infliximab as a suspected drug; of these, 34 
cases were categorized as preventable.
Compared to infliximab originator, biosimilars had an 
increased probability of being reported as suspected in 
individual case safety reports related to the occurrence of 
infusion reactions and a decreased probability of being 
reported as suspected in individual case safety reports 
reporting infections or lack of efficacy.
rheumatoid arthritis [11]. After the approval of  Remsima® 
and  Inflectra®, amongst the many post-marketing studies that 
have evaluated their safety profile, a recent pharmacovigi-
lance study performed by our group confirmed, through the 
analysis of data reported in individual case safety reports 
(ICSRs), the comparable safety profile of infliximab origina-
tor and its biosimilars in five Italian regions [12].
An important pillar of biosimilars’ development is the 
evaluation of the safety profile. Safety issues mainly include 
immunogenicity and an increased risk for other adverse 
effects, such as serious infections [9, 13–18]. Immunogenic-
ity can induce the occurrence of acute infusion reactions, 
delayed hypersensitivity reactions, and loss of efficacy as 
a direct consequence of the production of neutralizing and 
non-neutralizing antidrug antibodies (ADAs) [8, 19–21]. In 
virtue of the aforementioned safety concerns, specific risk 
minimization measures have been introduced for infliximab, 
such as the contraindication for patients with a history of 
hypersensitivity, tuberculosis or other severe infections, 
and special warnings and precautions related to the co-
administration of infliximab with other biological medici-
nal products or in patients affected by malignancies or lym-
phoproliferative disorders. All these elements are reported 
in infliximab’s Summary of Product Characteristics (SPC) 
[6]. However, to date, it is not known to what extent these 
measures are followed in routine clinical practice.
In this regard, it should be highlighted that adverse drug 
reactions (ADRs) that occur in the presence of risk factors 
are the most preventable type of ADRs and, for them, the 
World Health Organization claims an improved effort for 
their identification and minimization. While several stud-
ies have been conducted for a panel of medicinal products 
[22–24], to date, there is no available evidence for infliximab 
on the magnitude of preventable ADRs identified through 
spontaneous reporting systems. To fill this gap in knowl-
edge, for this study, we retrieved from the Italian Pharma-
covigilance Database all ICSRs that reported infliximab as 
the suspected drug among those sent through Campania, 
Lombardy, Sicily, Tuscany, and Veneto spontaneous report-
ing systems; we searched for preventable and not preventable 
ADRs; and we compared the probability of reporting infec-
tions, infusion reactions, lack of efficacy, and hypersensitiv-
ity as ADRs as opposed to other types of ADRs between 
originator and biosimilars of infliximab.
2  Methods
2.1  Study Design
A safety evaluation study was conducted based on data 
reported in the Italian Pharmacovigilance Database, and 
included a case series of preventable/not-preventable ADRs.
1 Introduction
With the gradual expiration of patents of biotech drugs, new 
copy versions of these medicines have become available for 
patients—the biosimilars. Such drugs are defined by the 
European Medicines Agency (EMA) as “a biological medi-
cine highly similar to another biological medicine already 
approved in the EU” [1]. EMA has led the way in biosimilar 
regulation through the implementation of a solid framework 
for their development and approval, and with the compara-
bility exercise, which aims to ensure that the biosimilar and 
the reference medicine have the same features in terms of 
quality, efficacy, and safety [2–7].
From 2006 until September 2018, EMA authorized 46 
biosimilars [8]. Infliximab was the first biosimilar of a 
monoclonal antibody (mAb) to be approved. Infliximab is a 
chimeric mAb, acting as a tumor necrosis factor-α (TNF-α) 
blocker.
Infliximab was approved by EMA in 1999, under the 
market name of  Remicade®, as an intravenous injection for 
the treatment of Crohn’s disease, ulcerative colitis, rheu-
matoid arthritis, ankylosing spondylitis, psoriatic arthri-
tis, and plaque psoriasis [9]. Following  Remicade® patent 
expiration, four infliximab biosimilars obtained marketing 
authorization by EMA:  Remsima® and  Inflectra®, which 
were authorized in 2013, became available in Italy for use 
in clinical practice in 2015;  Flixabi®, which was approved in 
2016, obtained classification for pricing and reimbursement 
in Italy in May 2017;  Zessly®, approved by EMA in May 
2018, is not yet available on the Italian market.
The comparability exercise for  Remsima® and  Inflectra® 
consisted of several nonclinical and clinical studies, includ-
ing a phase 1 study in patients with ankylosing spon-
dylitis [10] and a phase 3 study in patients affected by 
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2.2  Data Source
For the purpose of this study, we retrieved from the Italian 
Pharmacovigilance Database all ICSRs that reported inf-
liximab as the suspected drug among those sent through 
Campania, Lombardy, Sicily, Tuscany, and Veneto spontane-
ous reporting systems from October 2015 to October 2017. 
Overall, these regions cover almost 30 million citizens, 
49% of the Italian population. In Italy, healthcare profes-
sionals and consumers can send ICSRs directly to the local 
pharmacovigilance manager (local health unit/hospital) or 
to the marketing authorization holder/national competent 
authority. Local pharmacovigilance managers perform the 
data entry into the Italian Pharmacovigilance Database. 
Marketing authorization holders, furthermore, perform the 
data entry directly in EudraVigilance. However, through re-
routing, ICSRs collected on the Italian national territory are 
automatically transferred to the Italian Pharmacovigilance 
Database. Prior to data entry, both local pharmacovigilance 
managers and marketing authorization holders evaluate the 
quality and validity of each ICSR, and whenever neces-
sary, they retrieve additional information for the causality 
assessment.
Data on the utilization of infliximab’s products in Cam-
pania, Lombardy, Sicily, Tuscany, and Veneto were obtained 
from IMS Health.
2.3  Case‑by‑Case Assessment
As part of their routine pharmacovigilance activities, Cam-
pania, Lombardy, Sicily, Tuscany, and Veneto Pharmacovig-
ilance Regional Centers perform the causality assessment for 
all drug–event couples reported through their spontaneous 
reporting systems using the Naranjo algorithm [25]. For this 
study, furthermore, a trained multiregional team composed 
of pharmacists and clinical pharmacologists experienced 
in pharmacovigilance assessed the preventability of ADRs 
using the P-method. The P-method [26] involves the use of a 
validated algorithm, which aims to assess the preventability 
of ADRs reported in ICSRs among those sent through spon-
taneous reporting systems. In our study, the preventability 
assessment was performed in two steps and exclusively for 
those ICSRs with a causality assessment that resulted as 
at least “possible” according to the Naranjo scale. In par-
ticular, the first step was the determination of the potential 
mechanism for ADRs. The second step was the evaluation 
of the critical criteria or risk factors for the development of 
an ADR, or rather, answering a questionnaire composed of 
20 questions for which assessors could answer positively, 
negatively or state that the question was “not applicable” or 
“unknown” for the case. If at least one positive answer was 
given, the case was classified as preventable (i.e., more than 
one critical criterion was detectable). If no positive answers 
were given, the case was classified as not preventable. Cases 
with insufficient information to assess critical criteria were 
classified as not assessable. Full agreement among clinical 
pharmacologists and pharmacists involved in the prevent-
ability assessment was reached for all preventable cases.
2.4  Statistical Analyses
We plotted the number of ICSRs involving infliximab, the 
number of infliximab vials distributed, and the relative 
reporting rate stratified by semester. According to our study 
aims, we presented a case series of all preventable cases 
involving infliximab as the suspected drug. Being aware of 
the limits of disproportionality methods for comparative 
drug safety analyses [27], we used the reporting odds ratio 
(ROR) to compare the probability of reporting infections, 
infusion reactions, lack of efficacy, and hypersensitivity 
as ADRs as opposed to other types of ADRs between inf-
liximab originator and biosimilars. A multivariable logistic 
regression model was used to adjust RORs by age, gen-
der, comorbidities, indication of use, region, and number 
of concomitant drugs/medications as shown by Rothman 
and colleagues [28]. In particular, the ROR was adjusted 
for the aforementioned covariates because previous studies 
have proved that confounding may potentially be reduced 
[29–31]. For descriptive purposes, clinical and demographic 
characteristics of cases, type of reporter, and the seriousness 
and outcome of ADRs stratified by originator/biosimilar 
were reported.
3  Results
From October 2015 to October 2017, 459 ICSRs reported 
infliximab as the suspected drug among those sent through 
Campania, Lombardy, Sicily, Tuscany, and Veneto regions’ 
spontaneous reporting systems. In the same period, 81,906 
vials of infliximab were distributed, resulting in a report-
ing rate of six ICSRs/1000 vials. In January 2017, for the 
first time, biosimilar vials reached over 50% of overall vials 
distributed in the aforementioned Italian regions, with an 
increasing trend over the years (Fig. 1). Immediately after 
the marketing authorization of infliximab biosimilars, an 
increase in the reporting rate of ICSRs for those drugs was 
observed (Fig. 2). For both originator and biosimilars, demo-
graphic and clinical characteristics are provided in Table 1. 
In total, 222 ICSRs reported  Remicade® as suspected and 
237 ICSRs reported biosimilars  (Remsima® and  Inflectra®). 
Patients who experienced an ADR to infliximab (both origi-
nator and biosimilars) had a mean age of 48.0 ± 15.5 years, 
and 54.5% of them were female. Therapeutic indications 
reported in ICSRs for  Remicade®,  Remsima® and  Inflectra® 
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were those authorized (rheumatoid arthritis 34%; Crohn’s 
disease 24.6%; ulcerative colitis 18.3%; spondylitis 16.3%; 
psoriasis 6.8%) (Table 1). The highest number of ICSRs 
sent to the Italian Pharmacovigilance Database were from 
Lombardy (38.1%) and Sicily (29.4%), followed by Tuscany 
(14.4%), Veneto (12.2%) and Campania (5.9%). More than 
60% of patients who experienced an ADR with infliximab 
were concomitantly receiving at least one further medica-
tion, and more than 80% of those patients had at least one 
comorbidity, mainly cardiac disorders, dyslipidemia, and 
acute/chronic infections (Table 1).  
3.1  Preventable Cases
In total, 34 cases out of 459 (7.41%) were considered as 
preventable (see the electronic supplementary material, 
Supplementary Table 1). The reporting rate of prevent-
able cases was four cases/10,000 vials distributed, and the 
underlying mechanism of ADRs was, for the majority of 
cases, susceptibility related (14/34; 41.2%) (Fig. 3). Thirty-
eight critical criteria related to healthcare professionals’ 
practices were detected. The most detected critical criteria 
were “documented hypersensitivity to administered drug or 
drug class” (12/38; 31.6%), “inappropriate prescription for 
patient’s underlying medical condition” (11/38; 28.9%) and 
“incorrect dose” (7/38; 18.4%).
3.2  Disproportionate Reporting of Infections, 
Infusion Reactions, Lack of Efficacy, 
and Hypersensitivity Between Biosimilars 
and Originator of Infliximab
In unadjusted analyses, biosimilars had an increased prob-
ability of being reported as suspected in ICSRs reporting 
hypersensitivity and infusion reactions as opposed to other 
types of ADRs when compared to  Remicade®. Analogously, 
biosimilars have, in unadjusted analyses, a reduced prob-
ability of being reported as suspected in ICSRs reporting 
lack of efficacy or infection (Fig. 4). In adjusted analy-
ses, aforementioned associations were found for infec-
tions (ROR 0.33; 95% confidence interval [CI] 0.12–0.89; 
p value = 0.029), lack of efficacy (ROR 0.35; 95% CI 
0.20–0.61; p value < 0.001) and infusion reactions (ROR 
4.09; 95% CI 1.26–13.32; p value = 0.019).
4  Discussion
This is the first study assessing the utilization pattern and the 
safety profile of infliximab products (through a spontaneous 
reporting system) as well as the magnitude of preventability 
of ADRs induced by these products. Our study shows that 
from October 2015 to October 2017, infliximab biosimilars’ 
utilization gradually increased in Italy, with an increase in 
the reporting rate of ICSRs for biosimilars. Overall, 459 
ICSRs reported infliximab as a suspected drug. All ICSRs 
reported as suspected a defined medical product, originator 
or biosimilar; in our study, no ICSRs reported as suspected 
infliximab without the identification of the brand name. This 
is in line with the current European regulation on post-mar-
keting biological medicines’ traceability that is aimed at the 
identification and distinction between biological medicines 
by the trade name and batch number in order to identify any 
safety signals associated with each biological product [32]. 
As expected, the number of ICSRs related to infliximab bio-
similars “physiologically” increased immediately after the 
marketing availability of those medicine in Italy, which can 
be partly interpreted as a result of the increasing number of 
patients being exposed to biosimilars. Meanwhile, a direct 
correlation between the increased attention that all biosimi-
lars, including those of infliximab, have received from cli-
nicians and patients and the increased reporting of ADRs 
induced by infliximab biosimilars cannot be excluded. In 
support of this could be the fact that, after reaching a peak, 
the reporting rate for infliximab biosimilars reduced substan-
tially despite the distributed vials of infliximab increasing 
over time.
Fig. 1  Trends of individual 
case safety reports (ICSRs) sent 
through the regional spontane-
ous reporting system and the 
number of vials of infliximab 
originator and biosimilars 
distributed in Campania, 
Lombardy, Sicily, Tuscany, and 
Veneto regions from October 
2015 to October 2017
0
20
40
60
80
100
120
140
160
180
200
0
2000
4000
6000
8000
10000
12000
14000
16000
October 2015 / March
2016
April 2016 /
September 2016
October 2016 / March
2017
April 2017 / October
2017
N
um
be
r o
f I
CS
Rs
N
um
be
r o
f v
ia
ls
Originator_vials Biosimilars_vials Originator_ICSRs Biosimilars_ICSRs
611Utilization and Safety Profiles of Infliximab Originator Versus Biosimilars in Italy
In our study, the mean age of patients who experienced 
an ADR was 48.0 ± 15.5 years; this is in line with what is 
reported in the literature regarding the mean age of onset 
of the diseases for which infliximab is indicated [33, 34]. 
ADRs occurred slightly more frequently in female patients 
compared to male ones. This is not surprising considering 
that a higher prevalence of use of infliximab could be found 
in the female population, due to a higher prevalence of dis-
eases for which this drug is indicated, including Crohn’s 
disease [35] and rheumatoid arthritis [36]. Moreover, female 
patients have a greater risk of developing an ADR compared 
with male ones, mainly for gender-related differences related 
to pharmacokinetic, immunological and hormonal factors 
[14, 37, 38]. According to our results, arthritis, Crohn’s dis-
ease and ulcerative colitis were more commonly reported 
as therapeutic indications in ICSRs; this could be explained 
by the different prevalence of those diseases. As a matter of 
fact, the prevalence of all immune-mediated inflammatory 
diseases in Western countries ranges from 5 to 7%, with a 
higher prevalence for rheumatoid arthritis and inflamma-
tory bowel diseases, followed by ankylosing spondylitis 
and psoriasis [39, 40]. We also found that 45% of patients 
who experienced ADRs induced by infliximab originator 
received the drug for the treatment of rheumatoid arthritis, 
while more than 50% of patients who experienced ADRs 
induced by infliximab biosimilars received the drug for the 
treatment of inflammatory bowel diseases (Crohn’s disease 
and ulcerative colitis). In our opinion, these differences 
could be a direct consequence of the higher acceptance of 
biosimilars by rheumatologists compared to gastroenterolo-
gists, who seem to be more reluctant to accept biosimilars 
[41]. On the other hand, the regional differences that we 
have found among Italian regions could be directly related 
to a different use of biosimilars in clinical practice, mainly 
due to decrees that have regulated biosimilars’ prescription 
as well as ADR reporting. This heterogeneity in biosimilars’ 
utilization, which could be linked to different reporting fea-
tures, was previously found in another study performed in a 
real-life setting [42].
In our study, the majority of patients had one or more 
comorbidities and were concomitantly receiving further 
medications. This is not surprising considering that comor-
bidities, including infective, cardiovascular, renal, and can-
cer diseases, are commonly present in patients diagnosed 
with immune-mediated inflammatory diseases and hugely 
contribute to the burden of disease and impairment of 
quality of life [43, 44]. Moreover, it should be noted that 
immune-mediated diseases usually require combination 
therapy [45, 46].
Our results also show that 7.41% of all cases were consid-
ered as preventable. With regard to preventable ADRs due to 
a documented hypersensitivity, according to literature data, 
infliximab therapy is associated with a well-known risk of 
hypersensitivity reactions, the exact etiology and pathogen-
esis of which is still unclear. Considering that such ADRs 
could be potentially serious, several preventive measures 
have been proposed, such as instructions for infusion rates 
and preventive medications [47, 48]. Moreover, according to 
information reported in the infliximab’s SPCs [49] as well as 
in the literature [50], a history of hypersensitivity to inflixi-
mab represents a contraindication, and routine retreatment in 
patients who have already experienced serious infusion reac-
tions to infliximab should not be recommended. Among our 
cases, the second main cause of preventability was an inap-
propriate prescription according to patient’s characteristics, 
mainly related to the occurrence of infections or cancer in 
patients with a prior history of those conditions. It is widely 
recognized that, by inhibiting the activity of the immune 
system, infliximab may predispose patients to an increased 
risk of developing malignancies and infections [51–54]. This 
risk is statistically associated with chronic hepatitis B or C, a 
history of cancer and a history of infectious events [55–57]. 
Similarly, immunosuppression therapy is not recommended 
for at least 5 years after a diagnosis of cancer [58–60]. An 
important finding of our study is that few preventable cases 
were related to incorrect dose administration. According to 
what is reported in Section 4.2 of the SPCs [6, 49], the clini-
cal response with infliximab is usually achieved with a dose 
Fig. 2  Infliximab origina-
tor and biosimilar reporting 
rates of individual case safety 
reports sent through Campania, 
Lombardy, Sicily, Tuscany, and 
Veneto regions’ spontaneous 
reporting systems from October 
2015 to October 2017
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that ranges from 3 to 7.5 mg/kg, depending on the therapeu-
tic indication. In our preventable cases, we have noticed that 
these recommended dosages were not respected. However, 
since the literature on this is still limited, we cannot exclude 
that the choice to treat the patient with a dose outside the 
recommended range was driven by an appropriate clinical 
evaluation performed by the clinician.
Table 1  Demographic and clinical characteristics of individual case safety reports having infliximab (originator and biosimilars) as suspected 
drug sent through Campania, Lombardy, Sicily, Tuscany, and Veneto Regions’ spontaneous reporting systems from October 2015 to October 
2017
SD standard deviation
Variable Level Biosimilars (n = 237) Originator (n = 222) Total (n = 459)
Age Mean (SD), years 48.5 (15.4) 47.4 (15.6) 48.0 (15.5)
Missing 16 3 19
Gender Female 126 (53.2) 124 (55.9) 250 (54.5)
Male 111 (46.8) 98 (44.1) 209 (45.5)
Indication for use Crohn’s disease 70 (29.5) 43 (19.4) 113 (24.6)
Rheumatoid arthritis 56 (23.6) 100 (45.0) 156 (34.0)
Ulcerative colitis 57 (24.1) 27 (12.2) 84 (18.3)
Psoriasis 23 (9.7) 8 (3.6) 31 (6.8)
Spondylitis 31 (13.1) 44 (19.8) 75 (16.3)
Region Lombardy 56 (23.6) 119 (53.6) 175 (38.1)
Campania 4 (1.7) 23 (10.4) 27 (5.9)
Sicily 81 (34.2) 54 (24.3) 135 (29.4)
Tuscany 50 (21.1) 16 (7.2) 66 (14.4)
Veneto 46 (19.4) 10 (4.5) 56 (12.2)
Number of reported concomitant drugs 1 136 (57.4) 145 (65.3) 281 (61.2)
2 35 (14.8) 23 (10.4) 58 (12.6)
3 25 (10.5) 19 (8.6) 44 (9.6)
4 11 (4.6) 7 (3.2) 18 (3.9)
5 12 (5.1) 3 (1.4) 15 (3.3)
6 6 (2.5) 4 (1.8) 10 (2.2)
7 3 (1.3) 10 (4.5) 13 (2.8)
8 2 (0.8) 3 (1.4) 5 (1.1)
9 2 (0.8) 5 (2.3) 7 (1.5)
≥ 10 5 (2.1) 3 (1.4) 8 (1.7)
Number of reported comorbidities 0 198 (83.5) 180 (81.1) 378 (82.4)
1 19 (8.0) 19 (8.6) 38 (8.3)
2 9 (3.8) 10 (4.5) 19 (4.1)
3 7 (3.0) 5 (2.3) 12 (2.6)
4 0 (0.0) 1 (0.5) 1 (0.2)
5 4 (1.7) 7 (3.2) 11 (2.4)
Cardiac disorders Yes 12 (5.1) 18 (8.1) 30 (6.5)
Respiratory disorders Yes 2 (0.8) 4 (1.8) 6 (1.3)
Dyslipidemia Yes 2 (0.8) 14 (6.3) 16 (3.5)
Diabetes mellitus Yes 1 (0.4) 1 (0.5) 2 (0.4)
Thyroid disorders Yes 4 (1.7) 0 (0.0) 4 (0.9)
Acute/chronic infections Yes 5 (2.1) 5 (2.3) 10 (2.2)
Psychiatric disorders Yes 6 (2.5) 1 (0.5) 7 (1.5)
Neurological disorders Yes 1 (0.4) 3 (1.4) 4 (0.9)
Electrolyte disorders Yes 3 (1.3) 7 (3.2) 10 (2.2)
Bone disorders Yes 3 (1.3) 5 (2.3) 8 (1.7)
Hematological disorders Yes 2 (0.8) 6 (2.7) 8 (1.7)
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Finally, we observed for infliximab originator and biosim-
ilars a different probability of being reported as suspected 
in ICSRs reporting infusion reactions, infections and lack 
of efficacy. During the last months, several post-marketing 
studies evaluating the safety profile of infliximab products 
were published in scientific literature. Most of these stud-
ies have evaluated the effects of the switch from infliximab 
originator to its biosimilars, revealing no safety or efficacy 
concerns [61–63]. Those studies that have compared the 
safety profile of originator and biosimilars have showed a 
similar rate of ADRs [64, 65], but to our knowledge, no 
study has yet compared the rate of occurrence of infections, 
loss of efficacy or infusion reactions. However, available 
studies suggest that infliximab biosimilars, along with 
 Remicade®, can be associated with the occurrence of such 
ADRs [66–68]. Furthermore, considering that among Italian 
regions, as dictated by the aforementioned decrees, the use 
of biosimilars is strongly recommended, especially in naïve 
patients, it is conceivable that the increased risk of infusion 
reactions in biosimilar users could be a direct consequence 
of the first administration of the drug. However, considering 
the differences in the decrees adopted by each of the Italian 
regions involved in this pharmacovigilance study, we cannot 
exclude their key role in the increase in the number of ICSRs 
related to infliximab biosimilars as well as in the reporting 
of specific ADRs versus others.
This study has a number of limitations and strengths. First 
of all, it is based on the spontaneous reporting system, and 
it is well known that it is affected by constraints that include 
underreporting, lack of clinical data, and improper causality 
Fig. 3  Flowchart of preventability assessment procedures performed for individual case safety reports (ICSRs) reporting infliximab as the sus-
pected drug
Fig. 4  Disproportionate reporting of infections, infusion reactions, lack of efficacy, and hypersensitivity between biosimilars and originator inf-
liximab. CI confidence interval
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attribution [69, 70]. Considering these intrinsic limitations, 
we cannot rule out the presence of other information not 
listed in ICSRs which might have influenced the proper 
evaluation of each report (i.e., the lack of the date of inflixi-
mab’s administration, the dose, concomitant clinical condi-
tions or medications). Despite these limitations, we present a 
comprehensive evaluation of safety data related to infliximab 
products in five Italian regions that account for almost 50% 
of the entire Italian population. Therefore, the safety data 
that we have collected for this study represent a cross-section 
of patients treated with infliximab in a real-life setting who 
experienced ADRs to these medical products. Furthermore, 
despite its intrinsic limitations, the spontaneous reporting 
system still represents a valuable and inexpensive tool, able 
to detect rare and serious ADRs not identified during premar-
keting clinical trials. In this regard, further pharmacovigi-
lance global data, such as those derived from the drug safety 
data repository Vigibase, could represent a valuable source of 
information able to confirm and improve our findings. More-
over, considering the historic moment in which we are living 
regarding issues relating to the utilization of biosimilars, we 
are able to share with the healthcare community reassuring 
data on the safety profile of these medicines. Nowadays, 
indeed, it is recognized worldwide that real world studies, 
performed during the post-marketing phase [71], represent 
one of the best sources of information regarding improving 
knowledge in the field of medicine safety profiles.
5  Conclusion
Our study showed that, along with a rapid increase in the uti-
lization of infliximab biosimilars in five Italian regions, there 
was also an increase in the ADR reporting rate, mainly as a 
result of the increasing number of patients being exposed to 
these medicines. Moreover, our results showed that 7.41% 
of ICSRs reported ADRs that were preventable. For these 
cases, the detected critical criteria were mainly related to 
“documented hypersensitivity to administered drug or drug 
class,” “inappropriate prescription for patient’s underlying 
medical condition” and “incorrect dose.” According to our 
results, no new safety issues have emerged for infliximab 
originator or its biosimilars.
Considering the potential advantages offered by the 
increase in biosimilar utilization in clinical practice, both 
for patients and healthcare systems, we believe that the 
use of biosimilars, including those of infliximab, should 
be undoubtedly supported in clinical practice. In order to 
achieve this aim and to counteract any doubts that persist 
among clinicians who prescribe biosimilars, a better knowl-
edge on the safety and efficacy of biosimilar drugs should be 
obtained from the promotion of real world studies and the 
analysis of real world data, which represent an innovative 
tool to implement knowledge on health services, generate 
new evidence, and respond to unsolved clinical questions. 
In this context, the conduct of prospective studies will help 
to fill this gap in knowledge and to better translate into clini-
cal practice valuable data on the safety profile of infliximab 
products, also aiming to reduce the burden of medical errors 
leading to preventable ADRs.
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